lanraplenib + gilteritinib

Lanraplenib + gilteritinib is an investigational oral combination therapy for relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. **Lanraplenib** is a potent, selective, next-generation spleen tyrosine kinase (SYK) inhibitor; SYK regulates intracellular signaling downstream of immunoreceptor tyrosine-based activation motifs (ITAM), which is implicated in oncogenic transcription regulation and myeloid progenitor proliferation[3]. **Gilteritinib** is a selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), an approved therapy for FLT3-mutant AML[2][3]. Preclinical studies and phase 1b/2 trials (KB-LANRA 1001) indicate that this combination provides strong antileukemic effects and deeper responses in FLT3-driven AML models compared to either agent alone[1][3][5]. Lanraplenib inhibits SYK-mediated transcriptional networks, while gilteritinib targets mutant FLT3, directly inhibiting leukemic cell survival and proliferation[3][1]. Developed primarily for relapsed/refractory FLT3-mutant AML, the combination is under trial to determine safety, pharmacokinetics, and efficacy endpoints[1][4][7].

Other names

lanraplenib + gilteritinib